Meisoindigo

Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity^[1][2]. In Vitro: Meisoindigo (Dian III; 5-20 μM; for 24?hours) inhibits growth of the AML cell lines^[1].
Meisoindigo (10?μM; for 24?hours) induces apoptosis of acute myeloid leukemia^[1].
Meisoindigo (5-10?μM; for 24?hours) causes cell-cycle arrest^[1].
Meisoindigo (5-10?μM; for 24?hours) increases the cleaved caspase-3 and pro-apoptotic Bak, and decreases Bcl-2 and Bcl-xL levels in HL-60 cells^[1].
Meisoindigo (10, 30, 50, 100, 150 μM; 24 hours) interdicts LPS-induced (1 μg/mL) NLRP3 inflammasome activation and M1/M2 polarization through down-regulation of TLR4 pathways after OGD/R in HT-22 and BV2 cells^[2].
In Vivo: Meisoindigo (Dian III; 50-150?mg/kg; IP; daily; for 14 days) has anti-leukemic activity in?vivo^[1].
Meisoindigo (2, 4, 8, 12 mg/kg; IP; before MCAO and 2 h after reperfusion) significantly reduces infarct volume, ameliorates neurological deficits 3 days after middle cerebral artery occlusion (MCAO) in Wild-type C57BL/6J mice (25-30 g). Meisoindigo reduces edema and lowers AQP4 expression in the brain^[2].